pharmaceutical contract manufacturing
Thermo Fisher Scientific has completed its $7.2 billion acquisition of CDMO Patheon, weeks after Lonza completed its $5.5 billion buyout of Capsugel.
Boehringer Ingelheim saw a significant rise in sales in the first half of the year, in part from a healthy jump in its contract manufacturing operations.
Albany-New York based AMRI has agreed to a buyout worth more than $920 million as the M&A market for contract manufacturers continues to run hot.
Charles River Laboratories has unloaded QS Pharma, a Philadelphia-area CDMO, months after picking it up as part of its $585 million buyout of WIL Research.
The massive CPhI show kicked off in Barcelona, Spain, on Tuesday with numbers that rival some small cities. An estimated 38,000 visitors from 150 countries swarmed through the facilities. They came to meet, look and listen to about 2,500 exhibitors.
After Sarepta Therapeutics this week won FDA approval for its controversial Duchenne muscular dystrophy drug, the CEO assured analysts it has a plan to ramp up production, plus a way to pay for it and the commercial launch.
Swedish CDMO Recipharm will get its first U.S. site with a deal to buy operations API and development operations from India’s Kemwell.
Pull out your tally of pharma job losses. We have another 260 to add, this time from Shire, which intends to shut down a Maryland plant over the next three years. Production at that plant will be